Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
October 2, 2025

Supplementary Figure S5 from Targeting Myeloid Trem2 Reprograms the Immunosuppressive Niche and Potentiates Checkpoint Immunotherapy in NASH-Driven Hepatocarcinogenesis

View Full Paper
Ask AI
Bookmark
Share

Authors

ZWZiyi WangYZYu ZhangXLXiangdong Li

Discussion

Loading...

Member takes

Overview

Targeting Trem2 reconfigures the immunosuppressive niche and improves checkpoint immunotherapy outcomes in NASH, indicating novel therapeutic strategies.

Key Points

  • Accumulation of monocytes and pro-inflammatory macrophages leads to increased degradation of NETs, enhancing therapeutic response.
  • This reprogramming by Trem2Δmye significantly alters the immunosuppressive tumor environment, indicating a potential treatment pathway.
  • Experimental models demonstrate that targeting Trem2 can boost the effectiveness of checkpoint immunotherapy in liver cancer.
  • Treatments could reshape the microenvironment in hepatocarcinogenesis, offering new insights for cancer immunotherapy approaches.

Cite This Study

Wang et al. (2025) studied this question.

synapsesocial.com/papers/68de68f183cbc991d0a2196chttps://doi.org/10.1158/2326-6066.30255481
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Supplementary Figure S4 from Targeting Myeloid Trem2 Reprograms the Immunosuppressive Niche and Potentiates Checkpoint Immunotherapy in NASH-Driven Hepatocarcinogenesis2025
  2. 2Supplementary Figure S6 from Targeting Myeloid Trem2 Reprograms the Immunosuppressive Niche and Potentiates Checkpoint Immunotherapy in NASH-Driven Hepatocarcinogenesis2025
  3. 3Supplementary Figure S3 from Targeting Myeloid Trem2 Reprograms the Immunosuppressive Niche and Potentiates Checkpoint Immunotherapy in NASH-Driven Hepatocarcinogenesis2025
  4. 4Supplementary Figure S1 from Targeting Myeloid Trem2 Reprograms the Immunosuppressive Niche and Potentiates Checkpoint Immunotherapy in NASH-Driven Hepatocarcinogenesis2025
  5. 5Supplementary Figure S2 from Targeting Myeloid Trem2 Reprograms the Immunosuppressive Niche and Potentiates Checkpoint Immunotherapy in NASH-Driven Hepatocarcinogenesis2025